Labcorp Holdings Inc. LH, or Labcorp, is prioritizing key specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology, aiming to tap into strong growth opportunities.
For my initial coverage of Labcorp, I'm calling it a hold, and an opportunity to earn a $0.72/share quarterly dividend on the leading clinical lab company in the US. The firm shows future growth ...
Labcorp Holdings Inc. LH, or Labcorp, is positioning itself for sustained growth with a series of strategic acquisitions and partnerships. With a growing emphasis on cell and gene therapy, the company ...
Laboratory Corp (NYSE: LH) on Thursday reported second-quarter 2025 adjusted earnings per share of $4.35, up from $3.94 a year ago, beating the consensus of $4.17. Sales increased 9.5% year-over-year ...
Thursday, Laboratory Corp (NYSE: LH) reported fourth-quarter 2024 adjusted earnings per share of $3.45, up from $3.30 a year ago, beating the consensus of $3.39. Sales increased 9.8% year-over-year to ...
Labcorp Holdings Inc. shares trade on the New York Stock Exchange under the ticker symbol LH. The company has a market capitalization of $21.05 billion and trades at a P/E ratio of 24.75. According to ...
Citi upgraded Charles River Laboratories (NYSE:CRL) and LabCorp (NYSE:LH) while downgrading Quest Diagnostics (NYSE:DGX), citing valuation-related arguments as the main reasons for the rating ...
The stock's fall snapped a two-day winning streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results